Algorae Pharmaceuticals Ltd (1AI) - Total Liabilities
Based on the latest financial reports, Algorae Pharmaceuticals Ltd (1AI) has total liabilities worth AU$111.25K AUD (≈ $78.72K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Algorae Pharmaceuticals Ltd to assess how effectively this company generates cash.
Algorae Pharmaceuticals Ltd - Total Liabilities Trend (2004–2025)
This chart illustrates how Algorae Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Algorae Pharmaceuticals Ltd (1AI) asset resilience to evaluate the company's liquid asset resilience ratio.
Algorae Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Algorae Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aneka Jaringan Holdings Bhd
KLSE:0226
|
Malaysia | RM179.27 Million |
|
Castor Maritime Inc
NASDAQ:CTRM
|
USA | $80.40 Million |
|
Hotel Shilla Co Ltd
KO:008775
|
Korea | ₩2.47 Trillion |
|
Energoaparatura S.A.
WAR:ENP
|
Poland | zł15.31 Million |
|
Hifab Group AB Series B
ST:HIFA-B
|
Sweden | Skr60.58 Million |
|
Euroconsultants SA
AT:EUROC
|
Greece | €6.35 Million |
|
Genomtec S.A.
WAR:GMT
|
Poland | zł5.84 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Algorae Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 1AI stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Algorae Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Algorae Pharmaceuticals Ltd (2004–2025)
The table below shows the annual total liabilities of Algorae Pharmaceuticals Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$169.76K ≈ $120.11K |
-4.87% |
| 2024-06-30 | AU$178.45K ≈ $126.26K |
-60.33% |
| 2023-06-30 | AU$449.86K ≈ $318.30K |
+88.02% |
| 2022-06-30 | AU$239.26K ≈ $169.29K |
-9.74% |
| 2021-06-30 | AU$265.08K ≈ $187.56K |
-48.30% |
| 2020-06-30 | AU$512.72K ≈ $362.78K |
-68.37% |
| 2019-06-30 | AU$1.62 Million ≈ $1.15 Million |
+242.39% |
| 2018-06-30 | AU$473.47K ≈ $335.01K |
-59.74% |
| 2017-06-30 | AU$1.18 Million ≈ $832.11K |
+84.97% |
| 2016-06-30 | AU$635.80K ≈ $449.87K |
+88.30% |
| 2015-06-30 | AU$337.65K ≈ $238.91K |
-72.62% |
| 2014-06-30 | AU$1.23 Million ≈ $872.45K |
+27.64% |
| 2013-06-30 | AU$966.00K ≈ $683.51K |
-17.44% |
| 2012-06-30 | AU$1.17 Million ≈ $827.85K |
+64.47% |
| 2011-06-30 | AU$711.40K ≈ $503.36K |
+1.09% |
| 2010-06-30 | AU$703.74K ≈ $497.94K |
-27.65% |
| 2009-06-30 | AU$972.64K ≈ $688.20K |
+36.19% |
| 2008-06-30 | AU$714.19K ≈ $505.34K |
-70.44% |
| 2007-06-30 | AU$2.42 Million ≈ $1.71 Million |
-1.87% |
| 2006-06-30 | AU$2.46 Million ≈ $1.74 Million |
+204.28% |
| 2005-06-30 | AU$809.16K ≈ $572.53K |
-69.29% |
| 2004-06-30 | AU$2.63 Million ≈ $1.86 Million |
-- |
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more